MaxBetto
< Back

Sarah Rokusek vs Monique Barry

Tennis
2025-09-11 04:57
Start: 2025-09-11 04:48

Summary

Pick: home
EV: 0.33

Current Odds

Home 18|Away 1.01
Best Odds

Match Info

Match key: Sarah Rokusek_Monique Barry_2025-09-11

Analysis

Summary: The away price looks severely overvalued; we project Sarah Rokusek at ~35% win probability which makes the 3.8 home price +EV versus the market. This is a high-uncertainty value play rather than a certainty.

Highlights

  • Market-implied probabilities are extreme and likely incorrect given player parity
  • Home price 3.8 > fair threshold ~2.857, yielding significant theoretical ROI

Pros

  • + Large margin between market implied chance and our estimated probability
  • + Current odds (3.8) translate to strong theoretical expected value (≈33% ROI)

Cons

  • - Very small sample and limited data on both players increases model uncertainty
  • - No H2H, injury, or on-site conditions to further validate the edge; market may move

Details

We see a large market disconnect: the away price (1.23, implied ~81%) is heavily favored despite both players having nearly identical career records (Sarah Rokusek 10-22, Monique Barry 10-21) and comparable surface experience. There is no H2H or injury info provided to justify such a skew. Using a conservative head-to-head assessment (players of very similar level, slight variance from sample noise), we estimate Sarah's chance materially above the market-implied 26.3% for the home moneyline. At our estimated true probability of 35%, the minimum fair price would be ~2.857 decimal; the available 3.8 represents positive expected value. We therefore recommend the home moneyline because the current odds (3.8) provide a substantial edge versus our probability model. Key caveats: both players have limited and similar results and the dataset is small, so uncertainty is high.

Key factors

  • Market implies Monique ~81% which is inconsistent with near-identical career records
  • Both players have similar win-loss records and surface histories (no clear edge)
  • No injury/H2H data provided; valuation relies on relative parity and market skew